Literature DB >> 2109790

Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

E Kerem1, M Corey, R Gold, H Levison.   

Abstract

To evaluate the relationship between Pseudomonas aeruginosa colonization and the development of lung disease, we studied 895 patients who attended our cystic fibrosis clinic between 1975 and 1988. The prevalence of P. aeruginosa colonization was 82%. Patients who acquired P. aeruginosa in the first year of life had a similar 10-year survival rate (85%) to that in patients who were colonized between the ages of 1 and 7 years (87%), and to that in patients colonized after the age of 7 years (78%). One year before colonization, mean age, forced expiratory volume in 1 second (FEV1), forced vital capacity, and forced expiratory flow in the mid-expiratory phase were similar to those in a group of patients who remained free of P. aeruginosa. No significant change in pulmonary function variables could be demonstrated 1 year and 2 years after the colonization. The rate and duration of hospitalization did not increase in the years after P. aeruginosa colonization compared with the years before colonization. By the age of 7 years, the mean percentage of predicted FEV1 was lower by 10% in patients who were already colonized by P. aeruginosa compared with those who were not colonized (p less than 0.01). A similar reduction in FEV1 was observed at all ages from 7 to 35 years, but no precipitate rate of decline in FEV1 could be associated with P. aeruginosa colonization. We conclude that although P. aeruginosa colonization is associated with 10% lower lung function, it does not cause an immediate and rapid reduction, as has been previously reported. The clinical course and the pulmonary deterioration in cystic fibrosis after P. aeruginosa colonization is a gradual and variable process.

Entities:  

Mesh:

Year:  1990        PMID: 2109790     DOI: 10.1016/s0022-3476(05)82653-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  76 in total

Review 1.  Cystic fibrosis.

Authors:  P Robinson
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

Review 2.  Growth and growth charts in cystic fibrosis.

Authors:  Leena Patel; Moira Dixon; T J David
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

3.  Role of energy metabolism in conversion of nonmucoid Pseudomonas aeruginosa to the mucoid phenotype.

Authors:  J M Terry; S E Piña; S J Mattingly
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

4.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

5.  Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.

Authors:  William G Flight; Ann Smith; Christopher Paisey; Julian R Marchesi; Matthew J Bull; Phillip J Norville; Ken J Mutton; A Kevin Webb; Rowland J Bright-Thomas; Andrew M Jones; Eshwar Mahenthiralingam
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

6.  Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.

Authors:  Ateesha Farah Mohamed; F Reed Johnson; Maria-Magdalena Balp; Frederico Calado
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

Review 7.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

8.  Perspectives of longitudinal growth in cystic fibrosis from birth to adult age.

Authors:  G Haeusler; H Frisch; T Waldhör; M Götz
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

10.  Genetic determinants of Pseudomonas aeruginosa colonization in cystic fibrosis patients in Canada.

Authors:  M De Braekeleer; C Allard; J P Leblanc; G Aubin; F Simard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.